Endometrial Cancer Clinical Trials

∙ Patients are eligible to participate on this study only if they meet all of the following inclusion criteria.

• Has read and understands the informed consent form (ICF) and has given written informed consent prior to any study procedures

• Have surgically staged IIIC, pathologically confirmed endometrial cancer of any histologic subtype and be eligible for adjuvant chemoradiation followed by chemotherapy (Note: Surgical staging is defined as total hysterectomy and lymph node assessment.)

• Enrolled within 8 weeks of surgery and started treatment within 10 weeks of surgery

• Age ≥ 18 years

• Performance Status of ECOG 0 or 1 (see Performance Status Criteria)

• Adequate hematologic function within 14 days prior to enrollment defined as follows:

‣ Hemoglobin ≥ 9 g/dL

⁃ Platelets ≥ 100,000/mcl

⁃ Absolute neutrophil count (ANC) ≥ 1,500/mcl

• Adequate renal function within 14 days prior to enrollment defined as follows: Creatinine

• ≤ 2 x laboratory upper limit of normal (ULN) or CrCl ≥60ml/min

• Adequate hepatic function within 14 days prior to enrollment defined as follows:

‣ Bilirubin ≤ 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level ≤ 2 x ULN may be enrolled)

⁃ ALT and AST ≤ 2.5 x ULN

• Adequate coagulation within 14 days prior to enrollment defined as INR or PT/aPTT ≤ 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.

⁃ Prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial (i.e. non-melanomatous skin cancer).